These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2565508)

  • 1. Jaundice in HIV positive haemophiliac.
    Holmes J; Clements D
    Lancet; 1989 May; 1(8645):1027. PubMed ID: 2565508
    [No Abstract]   [Full Text] [Related]  

  • 2. [Oral amphotericin B inefficacy in the treatment of fluconazole++ resistant oropharyngeal candidiasis in HIV-positive patients].
    Laguna F; Valencia E; Polo R; Moreno V; González-Lahoz JM
    Rev Clin Esp; 1996 Dec; 196(12):878-9. PubMed ID: 9132869
    [No Abstract]   [Full Text] [Related]  

  • 3. Fluconazole-induced jaundice.
    Franklin IM; Elias E; Hirsch C
    Lancet; 1990 Sep; 336(8714):565. PubMed ID: 1975057
    [No Abstract]   [Full Text] [Related]  

  • 4. Gamma-interferon treatment for resistant oropharyngeal candidiasis in an HIV-positive patient.
    Bodasing N; Seaton RA; Shankland GS; Pithie A
    J Antimicrob Chemother; 2002 Nov; 50(5):765-6. PubMed ID: 12407143
    [No Abstract]   [Full Text] [Related]  

  • 5. Cavitating pulmonary cryptococcosis developing in an HIV antibody patient despite prior treatment with fluconazole.
    Coker RJ; Bell D; Peters BS; Murphy SM
    Genitourin Med; 1992 Feb; 68(1):42-4. PubMed ID: 1548011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Candida humicola infection of the central nervous system in an HIV-infected patient: a case report].
    Rogowska-Szadkowska D; Wiercińska-Drapało A; Borzuchowska A; Prokopowicz D
    Przegl Epidemiol; 1997; 51(4):465-9. PubMed ID: 9562797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-dose therapy for oral candidiasis with fluconazole in HIV-infected adults: a pilot study.
    Chave JP; Cajot A; Bille J; Glauser MP
    J Infect Dis; 1989 Apr; 159(4):806-7. PubMed ID: 2538523
    [No Abstract]   [Full Text] [Related]  

  • 8. [Candida albicans morphotypes and in vitro adhesivity to cells of the human oral mucosa in HIV-positive and AIDS patients after exposure of blastospores to fluconazole. II].
    Spadari E; Arosio M; Malighetti V; Bellotti MG; Artini MZ; Spadari F; Riviera L
    Minerva Stomatol; 1998; 47(7-8):293-7. PubMed ID: 9793362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stevens-Johnson syndrome after fluconazole.
    Gussenhoven MJ; Haak A; Peereboom-Wynia JD; van 't Wout JW
    Lancet; 1991 Jul; 338(8759):120. PubMed ID: 1676446
    [No Abstract]   [Full Text] [Related]  

  • 10. Antifungal susceptibility of 95 yeast strains isolated from oral mycoses in HIV-negative and HIV-positive patients.
    Mareş M; Mareş M; Rusu M
    Bacteriol Virusol Parazitol Epidemiol; 2008; 53(1):41-2. PubMed ID: 19241996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Posaconazole: new indications. Prevention of invasive mycosis and treatment of oropharyngeal candidiasis: no therapeutic advantage.
    Prescrire Int; 2008 Dec; 17(98):233. PubMed ID: 19422144
    [No Abstract]   [Full Text] [Related]  

  • 12. Haemodialysis for a haemophiliac with immunodeficiency virus.
    Propper DJ; Dawson AA; Bennett B; Catto GR
    Br J Haematol; 1988 Nov; 70(3):381. PubMed ID: 3207632
    [No Abstract]   [Full Text] [Related]  

  • 13. Relative growth measurement of Candida species in a single concentration of fluconazole predicts the clinical response to fluconazole in HIV infected patients with oral candidosis.
    Cartledge JD; Midgley J; Gazzard BG
    J Antimicrob Chemother; 1996 Feb; 37(2):275-83. PubMed ID: 8707737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS.
    Hegener P; Troke PF; Fätkenheuer G; Diehl V; Ruhnke M
    AIDS; 1998 Nov; 12(16):2227-8. PubMed ID: 9833866
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection.
    Vazquez JA; Skiest DJ; Tissot-Dupont H; Lennox JL; Boparai N; Isaacs R
    HIV Clin Trials; 2007; 8(2):86-97. PubMed ID: 17507324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posaconazole for the management of mucosal candidiasis.
    Vazquez JA
    Future Microbiol; 2007 Jun; 2(3):245-56. PubMed ID: 17661697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Oropharyngeal candidiasis resistant to fluconazole in patients infected by HIV].
    Drobacheff C; Manteaux A; Millon L; Reboux G; Barale T; Laurent R
    Ann Dermatol Venereol; 1996; 123(2):85-9. PubMed ID: 8761757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of the management of oral candidiasis associated with HIV/AIDS.
    Albougy HA; Naidoo S
    SADJ; 2002 Dec; 57(11):457-66. PubMed ID: 12674866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fluconazole in the treatment of esophageal, bronchial and oral candidiasis in patients with ARC and AIDS].
    Gritti FM; Raise E; Di Salvo S; Vannini V; Lanzoni G; Cucci AM
    G Ital Chemioter; 1988; 35(1-3):61-8. PubMed ID: 2855730
    [No Abstract]   [Full Text] [Related]  

  • 20. Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives.
    Devenport MH; Crook D; Wynn V; Lees LJ
    Br J Clin Pharmacol; 1989 Jun; 27(6):851-9. PubMed ID: 2547410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.